Longs
+1
Apr 19, 2026
•
12 min read
Why Nektar Therapeutics atopic dermatitis (AtD) drug could be significantly undervalued despite being a potential second-line drug treatment option
Merger Arb
Mar 17, 2026
13 min read
A quick walkthrough on the math post-deal break, and could LNSR still be compelling as a standalone company?
Special Situation
Feb 16, 2026
8 min read
Why this prized restaurant asset could strike up a bidding war amongst bidders looking to shore up their position in the quick service restaurant (QSR) space. Potential return could be in excess of 35%.
Feb 4, 2026
19 min read
Why we think this biotech trade, while popular, has limited downside risk in the event no suitor comes to scoop them up.
+2
Nov 13, 2025
25 min read
Going over earnings and our thoughts given updated information
Oct 21, 2025
11 min read
Why prioritizing deleveraging alone leads to unrealized equity appreciation
Sep 8, 2025
23 min read
An update on DKS/FL, LNSR and new ideas for PRPL and LE
Bankruptcy
Aug 25, 2025
22 min read
Why a slimmed down version of Weight Watchers might be poised to take on the next stage of weight loss
+3
Jun 5, 2025
21 min read
SHCO, LNSR, LQDA, CPRI, GENK, DKS, and HIMS
Apr 13, 2025
10 min read
Why we still think CPRI shareholders can make an outsized return from selling Versace
Mar 19, 2025
18 min read
Taking a look at the CPRI trade w/ new info and why BBW is looking good after that earnings print
Jan 21, 2025
24 min read
Going over SHCO, LQDA, Capri (CPRI), Tile Shop (TSSH), and the FDA.
Nov 17, 2024
Portfolio Update #8
Sep 8, 2024
28 min read
Looking at the most recent documents leading up to the
May 8, 2024
33 min read
Rebuttals against core complaints, backed by data and research
Mar 25, 2024
What's taking so long for the deal to close (or not)?
Feb 12, 2024
Recap on Interactive Strength (TRNR), Inspire Veterinary Partners (IVP) and iRobot (IRBT) with an update on Capri Holdings (CPRI)
Event-Driven
Jul 23, 2023
Dissecting a U.S. Army contract that could reshape the future of Red Cat Holdings
